Previous 10 | Next 10 |
home / stock / lexxw / lexxw news
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug-delivery platforms, has submitted its much-anticipated Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”). The application covers HYPER-H23-1, the company...
KELOWNA, BC / ACCESSWIRE / January 30, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX; LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that, on January 29, it submitted its much-anticipated Investigational New Drug ("IND") application with the U.S. F...
(TheNewswire) Kelowna, British Columbia – TheNewswire -- January 30, 2024 – Lexaria Bioscience Corp. (Nasdaq:LEXX ) (Nasdaq: LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that, on J...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug-delivery platforms, has released a shareholder letter from CEO Chris Bunka. In the letter, Bunka notes that near the end of 2023, 446 companies on the NASDAQ were trading under $1 and at risk of being delisted compared to almos...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today unveiled a comprehensive planned applied research program to thoroughly evaluate DehydraTECH for the improved delivery of GLP-1 drugs, designed to support prospective commercial partnering with global ...
(TheNewswire) Extensive work program designed to support commercial discussions. Kelowna, British Columbia – TheNewswire - January 16, 2024 – Lexaria Bioscience Corp. (Nasdaq:LEXX ) (Nasdaq: LEXXW) (the “Company” or “Lexaria...
(TheNewswire) Final results from a human pilot study show DehydraTECH TM -powered semaglutide outperforms Rybelsus ® : Sustained higher levels of semaglutide in blood; Better blood glucose control; Faster achievement of peak drug deli...
KELOWNA, BC / ACCESSWIRE / December 7, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that the Company's anticipated submission of an Investigational New Drug ("IND") application with the U.S. Foo...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug-delivery platforms, is reporting additional positive interim results from its human pilot study evaluating DehydraTECH(TM) technology for the oral delivery of the glucagon-like peptide-1 (“GLP-1”) drug s...
DehydraTECH TM -powered semaglutide achieved these benefits in a human pilot study compared to Rybelsus ® : Sustained lower levels of blood glucose from baseline including nearly 10x lower after 24 hours; Lower blood-glucose spike after eating; and Successful first-ever D...
News, Short Squeeze, Breakout and More Instantly...
Lexaria Bioscience Corp. Warrant Company Name:
LEXXW Stock Symbol:
NASDAQ Market:
Lexaria Bioscience Corp. Warrant Website:
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced the receipt of interim results from the first four weeks of dosing in its ongoing diabetes animal study WEIGHT-A24-1. The company noted that the results have already produced several notewort...
(TheNewswire) DehydraTECH appears to work with a second GLP-1 drug – liraglutide DehydraTECH appears to be working with semaglutide both with and without SNAC technology DehydraTECH-CBD is showing strong apparent performance relative to GLP-1 D...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug-delivery platforms, is preparing for growth by executing a strategic growth plan. A key element of the plan includes expanding the company’s management team to enable efficient handling of a greater workload of projects ...